JP2008508899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508899A5 JP2008508899A5 JP2007525666A JP2007525666A JP2008508899A5 JP 2008508899 A5 JP2008508899 A5 JP 2008508899A5 JP 2007525666 A JP2007525666 A JP 2007525666A JP 2007525666 A JP2007525666 A JP 2007525666A JP 2008508899 A5 JP2008508899 A5 JP 2008508899A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- adenovirus
- nucleic acid
- composition according
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 13
- 239000002245 particle Substances 0.000 claims 11
- 230000002950 deficient Effects 0.000 claims 8
- 230000010076 replication Effects 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 2
- 230000005030 transcription termination Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60032804P | 2004-08-09 | 2004-08-09 | |
| PCT/US2005/027658 WO2006020480A2 (en) | 2004-08-09 | 2005-08-05 | Adenoviral vector compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508899A JP2008508899A (ja) | 2008-03-27 |
| JP2008508899A5 true JP2008508899A5 (enExample) | 2008-09-18 |
Family
ID=35908044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525666A Withdrawn JP2008508899A (ja) | 2004-08-09 | 2005-08-05 | アデノウイルスベクター組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080063656A1 (enExample) |
| EP (1) | EP1786904A4 (enExample) |
| JP (1) | JP2008508899A (enExample) |
| CN (1) | CN1993462A (enExample) |
| AU (1) | AU2005274059A1 (enExample) |
| CA (1) | CA2575163A1 (enExample) |
| WO (1) | WO2006020480A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| MX338931B (es) | 2010-01-05 | 2016-05-06 | Vascular Biogenics Ltd | Composiciones y metodo para tratar gliobastoma (gbm). |
| MX342641B (es) | 2010-01-05 | 2016-10-07 | Vascular Biogenics Ltd | Metodos para uso de un agente adenoviral anti-angiogenico especifico. |
| CN103242433B (zh) * | 2012-02-14 | 2016-12-14 | 中国医学科学院病原生物学研究所 | 一种腺病毒非结构蛋白免疫原、其抗体及应用 |
| RU2744444C1 (ru) * | 2021-02-21 | 2021-03-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Применение средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 для ревакцинации населения (варианты) |
| CN117897167A (zh) * | 2021-05-13 | 2024-04-16 | 福奇生物制品公司 | 腺病毒辅助质粒 |
| CA3233100A1 (en) * | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| WO2024026302A2 (en) * | 2022-07-26 | 2024-02-01 | Asimov Inc. | Compositions and methods for adeno-associated viral production |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| WO2003077859A2 (en) * | 2002-03-13 | 2003-09-25 | Merck & Co., Inc. | Method of inducing an enhanced immune response against hiv |
-
2005
- 2005-08-05 CA CA002575163A patent/CA2575163A1/en not_active Abandoned
- 2005-08-05 EP EP05779520A patent/EP1786904A4/en not_active Withdrawn
- 2005-08-05 AU AU2005274059A patent/AU2005274059A1/en not_active Abandoned
- 2005-08-05 US US11/659,671 patent/US20080063656A1/en not_active Abandoned
- 2005-08-05 WO PCT/US2005/027658 patent/WO2006020480A2/en not_active Ceased
- 2005-08-05 JP JP2007525666A patent/JP2008508899A/ja not_active Withdrawn
- 2005-08-05 CN CNA2005800267346A patent/CN1993462A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | State‐of‐the‐art human adenovirus vectorology for therapeutic approaches | |
| Wang et al. | Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy | |
| Trivedi et al. | Evolving horizons: adenovirus vectors’ timeless influence on cancer, gene therapy and vaccines | |
| Yang et al. | Overcoming immunity to a viral vaccine by DNA priming before vector boosting | |
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| Sinn et al. | Lentivirus vector can be readministered to nasal epithelia without blocking immune responses | |
| Kaplan | Adenovirus-based cancer gene therapy | |
| Majhen et al. | Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field | |
| Fausther-Bovendo et al. | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? | |
| JP4787936B2 (ja) | 癌処理への使用のためのキメラアデノウィルス | |
| JP2023513611A5 (enExample) | ||
| JP2014503206A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| JP2022501055A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| Kreppel et al. | Capsid and genome modification strategies to reduce the immunogenicity of adenoviral vectors | |
| JP2009544318A5 (enExample) | ||
| JP2009515831A5 (enExample) | ||
| US20140140962A1 (en) | Viruses modified with unnatural moieties and methods of use thereof | |
| JP2003530307A5 (enExample) | ||
| JP2009504654A5 (enExample) | ||
| Spunde et al. | Recombinant viral vectors for therapeutic programming of tumour microenvironment: Advantages and limitations | |
| WO2009055491A3 (en) | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres | |
| Tessarollo et al. | Nonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy | |
| Hackett et al. | Four decades of adenovirus gene transfer vectors: History and current use |